Company news

ALX Oncology Holdings Inc. news in 2026

ALX Oncology Holdings Inc.'s news releases, calls and decks from 2026, newest first.

View company

ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 16, 2026

ALX Oncology to Present at Upcoming Investor Conferences

November 10, 2026

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

September 28, 2026

ALX Oncology to Present at Upcoming Investor Conferences in September

September 2, 2026

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

June 30, 2026

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

June 1, 2026

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

April 30, 2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

April 17, 2026

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

April 12, 2026

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 2, 2026

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 26, 2026

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

February 19, 2026

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

February 19, 2026

ALX Oncology Announces Pricing of Underwritten Offering

January 30, 2026

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

January 30, 2026

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

January 8, 2026

Calls in 2026

Decks in 2026